(2R,5R,6S)-6-methyloxane-2,5-diol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: (2R,5R,6S)-6-methyloxane-2,5-diol
• 化学式: C₆H₁₂O₃
• 分子量: 132.16
• InChiKey: ZCYMCBOUZXAAJG-KVQBGUIXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] ANTIBACTERIAL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS USING SAME<br/>[FR] COMPOSÉS ANTIBACTÉRIENS, COMPOSITIONS DE CEUX-CI ET PROCÉDÉS LES UTILISANT
  申请人：UNIV ROCKEFELLER

  公开号：WO2021242849A1

  公开（公告）日：2021-12-02

  The present disclosure includes novel compounds useful as antimicrobial agents. The present disclosure further includes methods useful The present disclosure further includes compositions and methods for treating or preventing a bacterial infection. The present disclosure further includes compositions and methods useful for preventing or reducing the growth or proliferation of microorganisms.

  本公开涉及新型化合物，可用作抗微生物剂。本公开还包括有用的方法，本公开还包括用于治疗或预防细菌感染的组合物和方法。本公开还包括用于预防或减少微生物生长或增殖的组合物和方法。
• Avermectins and Milbemycins as Anti-Mycobacterial Agents
  申请人：Thompson Charles J.

  公开号：US20140315842A1

  公开（公告）日：2014-10-23

  The present invention relates to methods of treating a mycobacterial infection. In particular, this invention relates to methods, uses and compounds for use in treating mycobacterial infections, including tuberculosis . For example, the compounds may be an avermectin or a milbemycin. The avermectin or milbemycin may be selected from, but not limited to, one or more of ivermectin, moxidectin or selamectin. Exemplary microbial infections that may be treated include, but are not limited to, infections caused by Mycobacterium tuberculosis, Mycobacterium bovis , other mycobacteria of the tuberculosis complex, and non-tuberculous mycobacteria, including Mycobacterium ulcerans.
• [EN] COMPOUNDS AND METHODS TO SENSITIZE CANCER CELLS TO CISPLATIN<br/>[FR] COMPOSÉS ET PROCÉDÉS POUR SENSIBILISER DES CELLULES CANCÉREUSES AU CISPLATINE
  申请人：DA ZEN THERANOSTICS INC

  公开号：WO2018075994A1

  公开（公告）日：2018-04-26

  The present invention generally relates to sensitizer compounds and their use to sensitize cancer and/or pre-cancerous cells of certain cancers to treatment with certain resistance-prone therapeutics used in cancer therapy. In embodiments, the conjugates of particular esters or amides of Near Infrared Dyes, are used as sensitizers to avoid or overcome therapeutic resistance once formed. In embodiments, the sensitizers include conjugates with Cisplatin, Simvastatin, Artemisinin, platin-based compounds or statins. In embodiments, the resistance prone cancer therapeutics include cisplatin, gemcitabine, doxorubicin, paclitaxel, docetaxel, and platin-based compounds. These may be administered in combination with the sensitizer, or the sensitizer itself may comprise an therapeutci-derived moiety conjugated to the sensitizer, for example as is the case for dye-CIS conjugated sensitizers. Alternatively, the sensitizer may be co-administered with one or more therapeutic.
• [EN] SIMVASTATIN AND CHEMOTHERAPEUTIC CONJUGATES WITH A HEPTAMETHINE CARBOCYANINE DYE RESENSITIZE HUMAN TUMORS TO HORMONAL ANTAGONISTS AND CHEMOTHERAPY<br/>[FR] SIMVASTATINE ET CONJUGUÉS CHIMIOTHÉRAPEUTIQUES AVEC COLORANT CARBOCYANINE HEPTAMÉTHINE RESENSIBILISANT DES TUMEURS HUMAINES VIS À VIS DES ANTAGONISTES HORMONAUX ET DE LA CHIMIOTHÉRAPIE
  申请人：CEDARS SINAI MEDICAL CENTER

  公开号：WO2018075996A1

  公开（公告）日：2018-04-26

  This application relates to dye-therapeutic moiety conjugates for imaging, targeting, and treating cancerous cells and/or tumors.